Targeting enzymes that control cancer cell state and fitness make cancer cells susceptible to intrinsic and immune-mediated killing, but drugging these pathways has been limited by poor tractability.
Larkspur develops small molecules that overcome these limitations, decreasing cancer cell fitness and sensitizing them to intrinsic and immune-driven mechanisms of killing.